Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Lexaria Bioscience Corp. - Common Stock (NQ:LEXX)

0.9000 +0.0448 (+5.24%)
Streaming Delayed Price Updated: 1:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Lexaria Bioscience Corp. - Common Stock

< Previous 1 2
...
19 20 21 22 23 24 25 26 Next >
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Study Results Expected to Demonstrate DehydraTECH-CBD’s Effectiveness Against Hypertension
Via CannabisNewsWire
Lexaria's Clinical Hypertension Study HYPER-H21-3 Nears Completion
KELOWNA, BC / ACCESSWIRE / December 14, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX) (NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that its human... 
From Lexaria Bioscience Corp.
Via AccessWire
Lexaria’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Exceeding $160B
Via Investor Brand Network
Lexaria Bioscience Corp.’s (NASDAQ: LEXX) Upcoming R&D Programs Targeting Global Markets Totaling Over $160 Billion
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Improving Bioavailability of Pharmaceuticals and Therapeutics
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Follow-Up Study Results Confirming DehydraTECH(TM)-CBD Arterial Stiffness Reduction
Via Investor Brand Network
Lexaria's DehydraTECHTM-CBD Reduces Arterial Stiffness, Results Confirmed in Human Clinical Study HYPER-H21-2
Results suggest broader applications for DehydraTECH-CBD beyond hypertension KELOWNA, BC / ACCESSWIRE / December 8, 2021 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Featured in Virtual Coverage of Benzinga’s Small Cap Conference
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Participate in Upcoming Benzinga Global Small Cap Conference
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarking on Potentially Pivotal Study to Evaluate DehydraTECH-CBD
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp.’s (NASDAQ: LEXX) DehydraTECH(TM) Demonstrates 10-20X Faster Nicotine Delivery in Recent Study
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) DehydraTECH(TM) Drug Delivery Technology Finding Multiple Medical Applications
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes
Via Investor Brand Network
Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces 2022 DehydraTECH(TM) R&D Programs, Including Investigations into Alzheimer’s Disease and Diabetes
Via CannabisNewsWire
Lexaria Bioscience Corp. (NASDAQ: LEXX) Embarks on its Most Ambitious Hypertension Clinical Study Yet: HYPER-H21-4
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Expands 2022 R&D Programs to Evaluate Potential Treatment Options for Alzheimer’s and Diabetes
Via Investor Brand Network
Lexaria 2022 R&D Programs to Include Investigations into Alzheimer's Disease and Diabetes
KELOWNA, BC / ACCESSWIRE / November 10, 2021 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces its plans for... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Death Intellectual Property
Lexaria Bioscience Corp. (NASDAQ: LEXX) Commences New Animal Study Evaluating Patented DehydraTECH(TM) Technology’s Efficacy in Reducing/Inhibiting Seizure Activity; Strengthens IP Portfolio
Via Investor Brand Network
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
Via CannabisNewsWire
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) to Expand Hypertension Clinical Program Through Most Ambitious Study to Date
Via Investor Brand Network
Lexaria Announces Ambitious New Hypertension Study HYPER-H21-4
- DehydraTECH-CBD also being evaluated in three other human clinical studies - Positive studies would support Lexaria's regulatory approval plans KELOWNA, BC / ACCESSWIRE / November 3, 2021 / Lexaria... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
CBDNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins R&D Program Comparing DehydraTECH-CBD with Generic CBD, Epidiolex
Via Investor Brand Network
Topics Intellectual Property
Lexaria Announces R&D Program to Compare First and Only FDA-Approved Prescription Cannabidiol
- New study EPIL-A21-1 will compare effectiveness of FDA-approved Epidiolex to DehydraTECHTM-CBD for reducing seizure activity KELOWNA, BC / ACCESSWIRE / November 1, 2021 / Lexaria Bioscience Corp.... 
From Lexaria Bioscience Corp.
Via AccessWire
Topics Intellectual Property
CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Earns Coverage for DehydraTECH(TM)’s Potential Market Reach, Multiple Uses
Via Investor Brand Network
< Previous 1 2
...
19 20 21 22 23 24 25 26 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.